Regencell Bioscience Holdings Limited, a traditional Chinese medicine developer, has filed Form F-1 Registration Statement on March 22, 2021 with the U.S. Securities and Exchange Commission to raise up to $18 million IPO. Pricing terms are yet to announce.
The company is an early-stage bioscience company that focuses on research, development and commercialization of traditional Chinese medicine for the treatment of neurocognitive disorders and degeneration.
The Hong Kong-based company was founded in 2014 and plans to list on the Nasdaq Capital Market under the symbol “RGCB.” Maxim Group LLC is the underwriters of the IPO.
The company engages Hunter Taubman Fischer & Li LLC as US Securities Counsel, and Friedman LLP Independent Auditor.
#ipo #nasdaq #tradisional #medicine #chinese #regencell
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
